News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Announces Eighteen Abstracts Selected for Presentation at 2009 AACR Annual Meeting

- ARRY-520 Selected for Oral Presentation and Educational Session -
- Seven Different Cancer Programs Highlighted -

BOULDER, Colo., Apr 06, 2009 (BUSINESS WIRE) -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that eighteen abstracts have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held from April 18-22, 2009, in Denver, Colorado. Presentations will disclose new findings about seven of its anti-cancer programs: ARRY-520, ARRY-543, ARRY-614, ARRY-380, AZD6244 (ARRY-886), AZD8330 (ARRY-704), and an emerging program for Chk1 inhibition.

The abstracts can be accessed through the AACR website, www.aacr.org. Abstract titles are provided below, however, please note that according to AACR policy, all data is embargoed until the time of the beginning of the presentation. All posters and presentations will be available as a PDF after they are presented on Array's website at www.arraybiopharma.com.

ARRY-520 / KSP Inhibitor:

  • Educational Session (Apr. 18, 1:00 - 3:00 PM): Biomarker driven optimization of novel KSP inhibitors
  • Abstract # 3867 (Apr. 21, 12:10 - 12:25 PM; Room 505-507): Degradation of the anti-apoptotic protein Mcl-1 correlates with mitotic cell death in response to the novel KSP inhibitor ARRY-520
  • Abstract # 4703 (Apr. 21, 1:00 - 5:00 PM; Hall B-F, Poster Section 37): In vivo and pharmacodynamic profiling of the KSP inhibitor ARRY-520 supports potent activity in hematological cancers and drug resistant tumors

ARRY-543 / ErbB-2/EGFR Inhibitor:

  • Abstract # 1757 (Apr. 19, 1:00 - 5:00 PM; Hall B-F, Poster Section 35): In vivo activity of ARRY-334543, a potent, small molecule inhibitor of EGFR/ErbB2 in combination with trastuzumab or docetaxel
  • Abstract # 3603 (Apr. 21, 8:00 AM - 12:00 PM; Hall B-F, Poster Section 31): ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study

ARRY-614 / p38 / Tie-2 Inhibitor:

  • Abstract # 331 (Apr. 19, 8:00 AM - 12:00 PM; Hall B-F, Poster Section 12): Activity of ARRY-614, an inhibitor of p38 map kinase and angiogenic targets, in hematologic malignancies

ARRY-380 / ErbB-2 Inhibitor:

  • Abstract # 1795 (Apr. 19, 1:00 - 5:00 PM; Hall B-F, Poster Section 36): In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2
  • Abstract # 5581 (Apr. 22, 8:00 AM - 12:00 PM; Hall B-F, Poster Section 37): In vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB-2 in combination with trastuzumab or docetaxel in a BT-474 human breast carcinoma xenograft model

AZD6244 (ARRY-886) / MEK Inhibitor:

  • Abstract # LB-129 (Apr. 20, 1:00 - 5:00 PM; Hall B-F, Poster Section 27): A Multi-institutional Study of AZD6244 (ARRY-142886) in Patients with Advanced Biliary Cancers
  • Abstract # 2742 (Apr. 20, 1:00 - 5:00 PM; Hall B-F, Poster Section 31): Activation of FOXO3a by AZD6244 (ARRY-142886) is essential for AZD6244-induced growth suppression in human cancer cells
  • Abstract # 2757 (Apr. 20, 1:00 - 5:00 PM; Hall B-F, Poster Section 31): Combination therapy with inhibitors of mTOR and MEK1/2 (AZD6244) kinases, shows enhanced apoptosis and tumor growth inhibition in preclinical models
  • Abstract # 2858 (Apr. 20, 1:00 - 5:00 PM; Hall B-F, Poster Section 35): Sorafenib in combination with AZD6244 inhibits tumor growth in ectopic and orthotopic models of human HCC
  • Abstract # 2922 (Apr. 20, 1:00 - 5:00 PM; Hall B-F, Poster Section 37): AZD6244 (ARRY-142886) pharmacokinetics and pharmacodynamics in tumor-bearing athymic nude mice
  • Abstract # 3702 (Apr. 21, 8:00 AM - 12:00 PM; Hall B-F, Poster Section 35): ERK-binding protein PEA-15 modulates ERK-targeted therapy in ovarian clear cell carcinoma
  • Abstract # 3699 (Apr. 21, 8:00 AM - 12:00 PM; Hall B-F, Poster Section 35): High levels of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

AZD8330 (ARRY-704) / MEK Inhibitor:

  • Abstract # 3696 (Apr. 21, 8:00 AM - 12:00 PM; Hall B-F, Poster Section 35): AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials

Chk1 Program:

  • Abstract # 1803 (Apr. 19, 1:00 - 5:00 PM; Hall B-F, Poster Section 37): Characterization of a novel, oral Chk1 inhibitor
  • Abstract # 4599 (Apr. 21, 1:00 - 5:00 PM; Hall B-F, Poster Section 34): Schedule-dependence and extended target-coverage of selective Chk1 inhibitors enhances the anti-tumor activity of chemotherapy in vivo

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our future plans for advancing certain of our proprietary drug programs, the potential to earn future milestone payments, license fees or royalty revenue, and the plans of our collaborators to further develop drugs we have out-licensed or on which we are collaborating. These statements involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2008, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of April 6, 2009. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

SOURCE: Array BioPharma Inc.

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
or
MacDougall Biomedical Communications
Cory Tromblee, 781-235-3060
ctromblee@macbiocom.com